New Hampshire is currently home to 321 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Lebanon, Manchester, Nashua and Portsmouth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Norris Cotton Cancer Center, Lebanon, New Hampshire
Conditions: Conventional Chondrosarcoma
Register for Updates
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
FEMALE
Ages:
Between 15 years and 55 years
Trial Updated:
01/02/2025
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates
HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's)
NCT06260228
Recruiting
The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Parkinson's Disease (PD) The main questions it aims to answer are: 1. Can the current HOBSCOTCH program be adapted for people with PD? 2. Will people with PD experience improved quality of life similar to that found in people with epilepsy after participating in the HOBSCOTCH program? Participants will be asked to: * at... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
12/19/2024
Locations: Dartmouth-Hitchcock, Lebanon, New Hampshire
Conditions: Parkinson Disease, Cognitive Dysfunction, Memory Disorders
Register for Updates
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Dartmouth-Hitchcock, Lebanon, New Hampshire
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
Positive Psychology for Smoking Cessation
NCT06632756
Recruiting
This study will examine how Positive Psychotherapy (PPT) may help people interested in quitting smoking, quit.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/06/2024
Locations: The Mental Health Center of Greater Manchester, Manchester, New Hampshire
Conditions: Mental Illness, Tobacco Dependence
Register for Updates
Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome
NCT05982795
Recruiting
The goal of this observational study is to learn about the effects of a specific cystic fibrosis therapy (Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy) on chronic sinonasal disease. The main questions it aims to answer are: 1. How does this therapy impact bacterial communities in the paranasal sinuses? 2. How does this therapy impact inflammation in the paranasal sinuses and olfactory cleft? 3. How does this therapy impact sense of smell and sinonasal disease burden in... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/06/2024
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Cystic Fibrosis
Register for Updates
Stroke Thrombectomy and Aneurysm Registry
NCT04994756
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
ALL
Ages:
Between 1 year and 120 years
Trial Updated:
12/05/2024
Locations: Portsmouth Regional Hospital, Portsmouth, New Hampshire
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Register for Updates
Technology-Assisted Implementation of a Mobile Health Program for Serious Mental Illness
NCT05725785
Recruiting
The goal of this clinical trial is to learn about how a digital training platform can enhance implementation and effectiveness of a validated mHealth system, called FOCUS, in people with serious mental illness. The main question this research aims to answer is whether patients obtain similar outcomes to previous FOCUS studies when using FOCUS with clinicians trained on a newly developed digital training platform. Participants will be asked to use the FOCUS smartphone application and receive mob... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Community Partners, Dover, New Hampshire
Conditions: Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Schizo Affective Disorder
Register for Updates
A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369
Recruiting
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Dartmouth Hitchcock, Lebanon, New Hampshire
Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Register for Updates
Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release
NCT06330545
Recruiting
The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are: • Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum? Participants will undergo: * Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection * Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
11/20/2024
Locations: Dartmouth Hitchcock, Lebanon, New Hampshire
Conditions: Dupuytren Contracture
Register for Updates
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: ActivMed Practices and Research, LLC., Portsmouth, New Hampshire
Conditions: Lower Respiratory Tract Illness
Register for Updates
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
NCT05900895
Recruiting
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Dartmouth Cancer Center, Lebanon, New Hampshire
Conditions: Metastatic Breast Cancer
Register for Updates